Stock Events

BerGenBio ASA 

$0.03
2
-$1.75-98.59% Wednesday 19:32

Statistics

Day High
0.03
Day Low
0.03
52W High
1.77
52W Low
0.03
Volume
37,305
Avg. Volume
0
Mkt Cap
156.93M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

14NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-1.03
-0.91
-0.79
-0.67
Expected EPS
-0.82
Actual EPS
-0.67

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BRRGF. It's not an investment recommendation.

About

Pharmaceuticals: Major
Health Technology
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Show more...
CEO
Mr. Martin Olin
Employees
40
Country
NO
ISIN
NO0010650013
WKN
000A2DPC0

Listings